Bill Text: NY A01379 | 2021-2022 | General Assembly | Introduced


Bill Title: Requires prescription information to be kept confidential.

Spectrum: Strong Partisan Bill (Democrat 13-1)

Status: (Introduced - Dead) 2022-01-05 - referred to health [A01379 Detail]

Download: New_York-2021-A01379-Introduced.html



                STATE OF NEW YORK
        ________________________________________________________________________

                                          1379

                               2021-2022 Regular Sessions

                   IN ASSEMBLY

                                     January 8, 2021
                                       ___________

        Introduced  by M. of A. CAHILL -- Multi-Sponsored by -- M. of A. ABINAN-
          TI, COLTON, CYMBROWITZ, ENGLEBRIGHT, GALEF, GLICK, GOTTFRIED, GUNTHER,
          MONTESANO, PAULIN,  PERRY,  L. ROSENTHAL,  WEPRIN  --  read  once  and
          referred to the Committee on Health

        AN  ACT  to  amend  the  public  health law, in relation to prescription
          privacy

          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:

     1    Section  1.  Legislative  findings and intent. Prescribing health care
     2  professionals should  have  a  reasonable  expectation  that  when  they
     3  prescribe  a  medication  for  a patient, that decision will not be made
     4  available to an outside third party. However, disclosure  of  individual
     5  identifying  information  about patients and prescribers enables pharma-
     6  ceutical companies to track the prescribing practices of  physicians  to
     7  target them for marketing, including gifts and payments.  This marketing
     8  can  distort  prescribing  practices  to  increase health care costs and
     9  undermine patient safety. The National Institutes of  Health  has  found
    10  that  nearly  one-third of the increase in prescription drug prices over
    11  the  last  decade  was  attributable  to  marketing-induced  shifts   in
    12  prescribing  practices.  Published  evidence  shows that prescribers are
    13  often encouraged by sales representatives to prescribe medications in  a
    14  manner  that has not been approved by the Federal Food and Drug Adminis-
    15  tration.
    16    Neither the state nor any other entity has  the  resources  to  effec-
    17  tively  counter  targeted  marketing  campaigns  that exceed hundreds of
    18  millions of dollars.
    19    The legislature finds that this legislation is  necessary  to  protect
    20  health care professionals and their patients from the abuses of targeted
    21  marketing that are made possible by the disclosure of individual identi-
    22  fying information.

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD01261-01-1

        A. 1379                             2

     1    § 2. Section 270 of the public health law is amended by adding two new
     2  subdivisions 15 and 16 to read as follows:
     3    15. "Individual identifying information" means information identifying
     4  or tending to identify a prescriber or patient, where the information is
     5  derived from or relates to a prescription for any drug or device.
     6    16.  "Marketing" means, but is not limited to, advertising, detailing,
     7  marketing, promotion, or any activity that could be  used  to  influence
     8  sales  or  market  share  of a drug or device, influence or evaluate the
     9  prescribing practices of a prescriber, or evaluate the effectiveness  of
    10  marketing practices or personnel.
    11    § 3. The public health law is amended by adding a new section 276-a to
    12  read as follows:
    13    § 276-a. Prescription privacy. 1. No prescriber, pharmacist, pharmacy,
    14  pharmacy benefits manager, health plan, insurer, third party payer, data
    15  transfer  intermediary,  drug manufacturer or wholesaler or their agents
    16  shall disclose, sell, transfer, exchange or use any individual identify-
    17  ing information to any person or entity for the purpose of marketing any
    18  drug or device.
    19    2. Notwithstanding subdivision one of this section, individual identi-
    20  fying information, subject to applicable law  may  be  disclosed,  sold,
    21  transferred  or  exchanged  to:  (a)  the  patient  to whom the original
    22  prescription was issued or a person  to  whom  the  prescribed  drug  or
    23  device may be delivered;
    24    (b)  a  person  legally authorized to issue or fill a prescription for
    25  the patient, a person who treats the patient, or a person  who  provides
    26  disease management or case management to the patient;
    27    (c)  an  officer,  inspector  or investigator for a government health,
    28  licensing or law  enforcement  agency  acting  under  appropriate  legal
    29  authority, where the request is made in writing;
    30    (d) a person authorized by a court order to receive such information;
    31    (e)  a health researcher who is otherwise authorized to have access to
    32  health records of the patient that include  the  individual  identifying
    33  information, for reasons including, but not limited to, conducting clin-
    34  ical trials or research regarding the effects of health care practition-
    35  er prescribing practices;
    36    (f) conduct drug safety evaluations, product recalls and specific risk
    37  management  plans,  as  identified  or requested by the federal food and
    38  drug administration, or its successor agency;
    39    (g) allow for the appropriate transfer of records that may take  place
    40  when ownership of a pharmacy is changed or transferred;
    41    (h)  the  patient's  health plan, insurer, or third party payer, or an
    42  agent, for the purpose of  payment  or  reimbursement  for  health  care
    43  services, including determining compliance with the terms of coverage or
    44  medical necessity, or utilization review;
    45    (i)  a  person or entity to whom, and for a purpose for which, disclo-
    46  sure or transfer is otherwise explicitly authorized or required by law;
    47    (j) a person or entity acting as an employee or agent of a  person  or
    48  entity  under  any  preceding  paragraph  of  this  subdivision, for the
    49  purpose of and consistent with that paragraph; or
    50    (k) a government entity as provided by law.
    51    3. Nothing in this section shall prohibit the collection, use,  trans-
    52  fer,  or  sale  of  patient  and prescriber data by zip code, geographic
    53  region, or medical specialty for marketing purposes, providing  it  does
    54  not contain individual identifying information.
    55    4. This section shall not prevent any person from disclosing, selling,
    56  transferring, or exchanging for value individual identifying information

        A. 1379                             3

     1  pertaining  to  that person, for any purpose; provided that the informa-
     2  tion does not include individual identifying information  pertaining  to
     3  any other person.
     4    5.  Nothing  in  this  section  shall  prohibit  a pharmacy from using
     5  patient information to  provide  care  management  educational  communi-
     6  cations  to a patient about the patient's health condition, adherence to
     7  a prescribed course of therapy or other information about the drug being
     8  dispensed, treatment options, or clinical trials.
     9    6. No person or entity to whom or which individual identifying  infor-
    10  mation  is  disclosed,  sold,  transferred  or exchanged shall disclose,
    11  sell, transfer or exchange it to any person or entity other than for the
    12  lawful  purpose  for  which  it  was  disclosed,  sold,  transferred  or
    13  exchanged  to  the  person or entity, and without satisfactory assurance
    14  that the recipient will safeguard the records from  being  disclosed  or
    15  used in the state for marketing purposes.
    16    7.  This  section  shall not be construed to authorize any disclosure,
    17  sale, transfer, or exchange of individual identifying  information  that
    18  is not otherwise authorized or required by law.
    19    8. In addition to the commissioner's authority to enforce this section
    20  under  section  twelve  of this chapter, the attorney general shall have
    21  the authority to bring an action to enforce compliance with this section
    22  without referral by the commissioner.
    23    § 4.  This act shall take effect on  the  one  hundred  eightieth  day
    24  after it shall have become a law.
feedback